The study aimed to compare the effectiveness and safety of other atypical antipsychotics (non-clozapine) plus electroconvulsive therapy (ECT) (NC+ECT) versus clozapine plus ECT (C+ECT) for treating treatment-resistant schizophrenia (TRS). Data of 32 patients with TRS who was receiving ECT were analysed. We compared clinical characteristics, response to treatment [defined as an improvement of 40% in the Brief Psychotic Rating Scale (BPRS) psychotic symptom subscale from pretreatment scores], change of Mini-mental Status Exam (MMSE) scores, and other adverse effects between the NC+ECT group (N= 16) and C+ECT group (N =16). We found that the overall response rate was 65.6% (75.8% for the NC+ECT group and 56.3% for the C+ECT g...
Two important clinical questions are whether there is a subtype of schizophrenia which responds diff...
Although clozapine is the most effective medication for treatment refractory schizophrenia, only 40%...
Background: Clozapine (clozaril, Mylan Products Ltd) is a first-choice treatment for people with ...
Background and purpose: In spite of discovering new antipsychotics in the past years, many patients ...
OBJECTIVE: Up to 70% of patients with treatment-resistant schizophrenia do not respond to clozapine....
This meta-analysis of randomized controlled trials (RCTs) examined the efficacy and safety of the co...
Schizophrenia is a complicated problem that millions of Americans struggle with and unfortunately, a...
This meta-analysis of randomized controlled trials (RCTs) examined the efficacy and safety of the co...
Introdução: A literatura mostra que cerca de 30% dos pacientes com esquizofrenia não respondem de fo...
Background: In treatment-resistant schizophrenia a combination of ECT with antipsychotics has been r...
Background Between 40% and 70% of people with treatment-resistant schizophrenia do not respond to c...
Schizophrenia is a psychiatric disease which affects one percent of population. It is most common in...
Objective:We sought to assess the effectiveness of clozapine augmentation with ECT (C+ECT) in patien...
BACKGROUND: Evidence for the management of inadequate clinical response to clozapine in treatment-re...
Introdução: A literatura mostra que cerca de 30% dos pacientes com esquizofrenia não respondem de fo...
Two important clinical questions are whether there is a subtype of schizophrenia which responds diff...
Although clozapine is the most effective medication for treatment refractory schizophrenia, only 40%...
Background: Clozapine (clozaril, Mylan Products Ltd) is a first-choice treatment for people with ...
Background and purpose: In spite of discovering new antipsychotics in the past years, many patients ...
OBJECTIVE: Up to 70% of patients with treatment-resistant schizophrenia do not respond to clozapine....
This meta-analysis of randomized controlled trials (RCTs) examined the efficacy and safety of the co...
Schizophrenia is a complicated problem that millions of Americans struggle with and unfortunately, a...
This meta-analysis of randomized controlled trials (RCTs) examined the efficacy and safety of the co...
Introdução: A literatura mostra que cerca de 30% dos pacientes com esquizofrenia não respondem de fo...
Background: In treatment-resistant schizophrenia a combination of ECT with antipsychotics has been r...
Background Between 40% and 70% of people with treatment-resistant schizophrenia do not respond to c...
Schizophrenia is a psychiatric disease which affects one percent of population. It is most common in...
Objective:We sought to assess the effectiveness of clozapine augmentation with ECT (C+ECT) in patien...
BACKGROUND: Evidence for the management of inadequate clinical response to clozapine in treatment-re...
Introdução: A literatura mostra que cerca de 30% dos pacientes com esquizofrenia não respondem de fo...
Two important clinical questions are whether there is a subtype of schizophrenia which responds diff...
Although clozapine is the most effective medication for treatment refractory schizophrenia, only 40%...
Background: Clozapine (clozaril, Mylan Products Ltd) is a first-choice treatment for people with ...